P
Philippe Aftimos
Researcher at Université libre de Bruxelles
Publications - 149
Citations - 2984
Philippe Aftimos is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 20, co-authored 113 publications receiving 1603 citations. Previous affiliations of Philippe Aftimos include Institut Jules Bordet.
Papers
More filters
Journal ArticleDOI
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Udai Banerji,Carla M.L. van Herpen,Cristina Saura,Fiona C Thistlethwaite,Simon Lord,Victor Moreno,Iain R. Macpherson,Valentina Boni,Christian Rolfo,Elisabeth G.E. de Vries,Sylvie Rottey,Jill J.J. Geenen,Ferry A.L.M. Eskens,Marta Gil-Martin,E.C. Mommers,Norbert P Koper,Philippe Aftimos +16 more
TL;DR: This first-in-human study assessed the safety and activity of trastuzumab duocarmazine in patients with advanced solid tumours and the proportion of patients achieving an objective response (complete response or partial response) according to RECIST version 1.1.
Journal ArticleDOI
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
Geraldine Gebhart,Laetitia E. Lamberts,Zena Wimana,Camilo Garcia,Patrick Emonts,Lieveke Ameye,Sigrid Stroobants,Manon T. Huizing,Philippe Aftimos,Jolien Tol,Wim J.G. Oyen,Danielle J. Vugts,Otto S. Hoekstra,Carolien P. Schröder,C. W. Menke-van der Houven van Oordt,Thomas Guiot,Adrienne H. Brouwers,Ahmad Awada,E.G.E. de Vries,Patrick Flamen +19 more
TL;DR: Pretreatment imaging of HER2 targeting, combined with early metabolic response assessment holds great promise for improving the understanding of tumor heterogeneity in mBC and for selecting patients who will/will not benefit from T-DM1.
Journal ArticleDOI
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Yacine Bareche,David Venet,Michail Ignatiadis,Philippe Aftimos,Martine Piccart,Françoise Rothé,Christos Sotiriou +6 more
TL;DR: The findings highlight for the first time the substantial genomic heterogeneity that characterize TNBC molecular subtypes, allowing for a better understanding of the disease biology as well as the identification of several candidate targets paving novel approaches for the development of anticancer therapeutics for TNBC.
Journal ArticleDOI
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin,Jean-Charles Soria,Anastasios Stathis,Jean-Pierre Delord,Solange Peters,Ahmad Awada,Philippe Aftimos,Mohamed Bekradda,Keyvan Rezai,Zhen Zeng,Azher Hussain,Susan N. Perez,Lillian L. Siu,Christophe Massard +13 more
TL;DR: Birabresib has dose-proportional exposure and a favorable safety profile, with clinical activity observed in NMC, and the recommended phase II dose in patients with select solid tumors is 80 mg once daily with continuous dosing.
Journal ArticleDOI
Effect of the COVID-19 pandemic on cancer treatment and research.
Kamal S Saini,Kamal S Saini,Begoña de las Heras,Javier de Castro,Ramachandran Venkitaraman,Martine Poelman,Gopalakrishnan Srinivasan,Monika Lamba Saini,Sanjeev Verma,Manuela Leone,Philippe Aftimos,Giuseppe Curigliano +11 more